Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| PTC THERAPEUTICS, INC.PTCT · Entity 3803 | CHIEF BUSINESS OFFICER | June 10, 2026 | June 12, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
PTC THERAPEUTICS, INC.
Report date June 10, 2026 · Filed June 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 73,411 |
Ending reported balance
After 2026-06-10 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2026-06-10 · Sale · Disposed 3,711 · Balance 73,411 F1: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on February 25, 2026. Row 2 · 2026-06-10 · Exercise / conversion · Acquired 17,566 · Balance 90,977 F1: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on February 25, 2026. Row 3 · 2026-06-10 · Sale · Disposed 17,566 · Balance 73,411 F1: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on February 25, 2026. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.01 · Expires 2028-01-02 | Direct | 0 |
Reported balance
After 2026-06-10 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-06-10 · Sale · Disposed 17,566 · Balance 0 F1: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on February 25, 2026. F2: Currently exercisable. |
Filing footnotes · ownership attribution and instrument terms
F1: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on February 25, 2026.
F2: Currently exercisable.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 08, 2025 Filed Sep 9, 2025 21:00 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,406 | $0.00 Strike: $11.23 | $0.00 |
DisclosureSEC source: 0001415889-25-023986 · form4-09092025_050901.xml · derivative · entry 19 Pauwels Eric · CIK 0001323212 · CHIEF BUSINESS OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,406 shares Expires 2027-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on June 4, 2025. F10 · derivative.exercise_date: Currently exercisable. Read SEC document |
| September 08, 2025 Filed Sep 9, 2025 21:00 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,713 | $0.00 Strike: $30.86 | $0.00 |
DisclosureSEC source: 0001415889-25-023986 · form4-09092025_050901.xml · derivative · entry 18 Pauwels Eric · CIK 0001323212 · CHIEF BUSINESS OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,713 shares Expires 2026-01-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on June 4, 2025. F10 · derivative.exercise_date: Currently exercisable. Read SEC document |
| September 08, 2025 Filed Sep 9, 2025 21:00 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionStock Option (Right to Buy) · Derivative | 8,528 | $0.00 Strike: $18.01 | $0.00 |
DisclosureSEC source: 0001415889-25-023986 · form4-09092025_050901.xml · derivative · entry 17 Pauwels Eric · CIK 0001323212 · CHIEF BUSINESS OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,528 shares Expires 2028-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on June 4, 2025. F10 · derivative.exercise_date: Currently exercisable. Read SEC document |
| September 08, 2025 Filed Sep 9, 2025 21:00 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionStock Option (Right to Buy) · Derivative | 6,017 | $0.00 Strike: $11.23 | $0.00 |
DisclosureSEC source: 0001415889-25-023986 · form4-09092025_050901.xml · derivative · entry 16 Pauwels Eric · CIK 0001323212 · CHIEF BUSINESS OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,406 Underlying: Common Stock · 6,017 shares Expires 2027-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on June 4, 2025. F10 · derivative.exercise_date: Currently exercisable. Read SEC document |
| September 08, 2025 Filed Sep 9, 2025 21:00 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionStock Option (Right to Buy) · Derivative | 16,698 | $0.00 Strike: $30.86 | $0.00 |
DisclosureSEC source: 0001415889-25-023986 · form4-09092025_050901.xml · derivative · entry 15 Pauwels Eric · CIK 0001323212 · CHIEF BUSINESS OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,713 Underlying: Common Stock · 16,698 shares Expires 2026-01-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on June 4, 2025. F10 · derivative.exercise_date: Currently exercisable. Read SEC document |
| September 08, 2025 Filed Sep 9, 2025 21:00 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 1,250 | $56.86 | $71,075.00 |
DisclosureSEC source: 0001415889-25-023986 · form4-09092025_050901.xml · nonDerivative · entry 14 Pauwels Eric · CIK 0001323212 · CHIEF BUSINESS OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 72,912 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on June 4, 2025. F9 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $56.50 to $57.10 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| September 08, 2025 Filed Sep 9, 2025 21:00 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionCommon Stock | 1,250 | $11.32 | $14,150.00 |
DisclosureSEC source: 0001415889-25-023986 · form4-09092025_050901.xml · nonDerivative · entry 13 Pauwels Eric · CIK 0001323212 · CHIEF BUSINESS OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 74,162 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on June 4, 2025. Read SEC document |
| September 08, 2025 Filed Sep 9, 2025 21:00 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 1,238 | $56.85 | $70,380.30 |
DisclosureSEC source: 0001415889-25-023986 · form4-09092025_050901.xml · nonDerivative · entry 12 Pauwels Eric · CIK 0001323212 · CHIEF BUSINESS OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 72,912 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on June 4, 2025. F8 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $56.50 to $57.14 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| September 08, 2025 Filed Sep 9, 2025 21:00 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionCommon Stock | 1,238 | $11.32 | $14,014.16 |
DisclosureSEC source: 0001415889-25-023986 · form4-09092025_050901.xml · nonDerivative · entry 11 Pauwels Eric · CIK 0001323212 · CHIEF BUSINESS OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 74,150 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on June 4, 2025. Read SEC document |
| September 08, 2025 Filed Sep 9, 2025 21:00 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 2,406 | $56.92 | $136,949.52 |
DisclosureSEC source: 0001415889-25-023986 · form4-09092025_050901.xml · nonDerivative · entry 10 Pauwels Eric · CIK 0001323212 · CHIEF BUSINESS OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 72,912 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on June 4, 2025. F7 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $56.57 to $57.45 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| September 08, 2025 Filed Sep 9, 2025 21:00 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionCommon Stock | 2,406 | $11.23 | $27,019.38 |
DisclosureSEC source: 0001415889-25-023986 · form4-09092025_050901.xml · nonDerivative · entry 9 Pauwels Eric · CIK 0001323212 · CHIEF BUSINESS OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 75,318 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on June 4, 2025. Read SEC document |
| September 08, 2025 Filed Sep 9, 2025 21:00 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 3,713 | $56.92 | $211,343.96 |
DisclosureSEC source: 0001415889-25-023986 · form4-09092025_050901.xml · nonDerivative · entry 8 Pauwels Eric · CIK 0001323212 · CHIEF BUSINESS OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 72,912 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on June 4, 2025. F6 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $56.60 to $57.45 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| September 08, 2025 Filed Sep 9, 2025 21:00 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionCommon Stock | 3,713 | $30.86 | $114,583.18 |
DisclosureSEC source: 0001415889-25-023986 · form4-09092025_050901.xml · nonDerivative · entry 7 Pauwels Eric · CIK 0001323212 · CHIEF BUSINESS OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 76,625 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on June 4, 2025. Read SEC document |
| September 08, 2025 Filed Sep 9, 2025 21:00 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 8,528 | $56.92 | $485,413.76 |
DisclosureSEC source: 0001415889-25-023986 · form4-09092025_050901.xml · nonDerivative · entry 6 Pauwels Eric · CIK 0001323212 · CHIEF BUSINESS OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 72,912 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on June 4, 2025. F5 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $56.50 to $57.38 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| September 08, 2025 Filed Sep 9, 2025 21:00 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionCommon Stock | 8,528 | $18.01 | $153,589.28 |
DisclosureSEC source: 0001415889-25-023986 · form4-09092025_050901.xml · nonDerivative · entry 5 Pauwels Eric · CIK 0001323212 · CHIEF BUSINESS OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 81,440 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on June 4, 2025. Read SEC document |
| September 08, 2025 Filed Sep 9, 2025 21:00 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 6,017 | $56.91 | $342,427.47 |
DisclosureSEC source: 0001415889-25-023986 · form4-09092025_050901.xml · nonDerivative · entry 4 Pauwels Eric · CIK 0001323212 · CHIEF BUSINESS OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 72,912 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on June 4, 2025. F4 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $56.50 to $57.42 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| September 08, 2025 Filed Sep 9, 2025 21:00 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionCommon Stock | 6,017 | $11.23 | $67,570.91 |
DisclosureSEC source: 0001415889-25-023986 · form4-09092025_050901.xml · nonDerivative · entry 3 Pauwels Eric · CIK 0001323212 · CHIEF BUSINESS OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 78,929 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on June 4, 2025. Read SEC document |
| September 08, 2025 Filed Sep 9, 2025 21:00 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 16,698 | $56.94 | $950,784.12 |
DisclosureSEC source: 0001415889-25-023986 · form4-09092025_050901.xml · nonDerivative · entry 2 Pauwels Eric · CIK 0001323212 · CHIEF BUSINESS OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 72,912 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on June 4, 2025. F3 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $56.59 to $57.41 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| September 08, 2025 Filed Sep 9, 2025 21:00 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | Exercise / conversionCommon Stock | 16,698 | $30.86 | $515,300.28 |
DisclosureSEC source: 0001415889-25-023986 · form4-09092025_050901.xml · nonDerivative · entry 1 Pauwels Eric · CIK 0001323212 · CHIEF BUSINESS OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 89,610 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on June 4, 2025. F2 · balance_after: Includes 272 shares of common stock acquired under the Issuer's employee stock purchase plan for the period ended June 30, 2025. Read SEC document |
| March 17, 2025 Filed Mar 18, 2025 21:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 300 | $58.31 | $17,493.00 |
DisclosureSEC source: 0001415889-25-008452 · form4-03182025_050301.xml · nonDerivative · entry 5 Pauwels Eric · CIK 0001323212 · CHIEF BUSINESS OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 72,640 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 13, 2024. F6 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $58.30 to $58.31 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| March 17, 2025 Filed Mar 18, 2025 21:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 3,340 | $57.67 | $192,617.80 |
DisclosureSEC source: 0001415889-25-008452 · form4-03182025_050301.xml · nonDerivative · entry 4 Pauwels Eric · CIK 0001323212 · CHIEF BUSINESS OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 72,940 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 13, 2024. F5 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $57.30 to $58.26 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| March 17, 2025 Filed Mar 18, 2025 21:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 1,085 | $56.62 | $61,432.70 |
DisclosureSEC source: 0001415889-25-008452 · form4-03182025_050301.xml · nonDerivative · entry 3 Pauwels Eric · CIK 0001323212 · CHIEF BUSINESS OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 76,280 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 13, 2024. F4 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $56.20 to $57.14 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| March 17, 2025 Filed Mar 18, 2025 21:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 2,037 | $55.24 | $112,523.88 |
DisclosureSEC source: 0001415889-25-008452 · form4-03182025_050301.xml · nonDerivative · entry 2 Pauwels Eric · CIK 0001323212 · CHIEF BUSINESS OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 77,365 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 13, 2024. F3 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $55.00 to $55.98 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| March 14, 2025 Filed Mar 18, 2025 21:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 4,458 | $55.19 | $246,037.02 |
DisclosureSEC source: 0001415889-25-008452 · form4-03182025_050301.xml · nonDerivative · entry 1 Pauwels Eric · CIK 0001323212 · CHIEF BUSINESS OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 79,402 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on December 13, 2024. F2 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $55.00 to $55.49 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| February 20, 2025 Filed Feb 21, 2025 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 1,567 | $50.12 | $78,544.31 |
DisclosureSEC source: 0001415889-25-005137 · form4-02212025_050211.xml · nonDerivative · entry 2 Pauwels Eric · CIK 0001323212 · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 83,860 F1 · shares: Represents shares automatically sold pursuant to an irrevocable sell to cover election entered into upon acceptance of the grant to satisfy tax withholding obligations in connection with the vesting of 5,500 RSUs from a February 15, 2024 grant of 22,000 RSUs and the vesting of 1,150 RSUs from a February 15, 2024 grant of 2,300 RSUs. Read SEC document |
| February 19, 2025 Filed Feb 21, 2025 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 1,378 | $50.10 | $69,032.29 |
DisclosureSEC source: 0001415889-25-005137 · form4-02212025_050211.xml · nonDerivative · entry 1 Pauwels Eric · CIK 0001323212 · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 85,427 F1 · shares: Represents shares automatically sold pursuant to an irrevocable sell to cover election entered into upon acceptance of the grant to satisfy tax withholding obligations in connection with the vesting of 5,500 RSUs from a February 15, 2024 grant of 22,000 RSUs and the vesting of 1,150 RSUs from a February 15, 2024 grant of 2,300 RSUs. Read SEC document |
| January 08, 2025 Filed Jan 10, 2025 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 2,136 | $44.50 | $95,052.00 |
DisclosureSEC source: 0001415889-25-001294 · form4-01102025_050109.xml · nonDerivative · entry 2 Pauwels Eric · CIK 0001323212 · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 86,805 F2 · shares: Represents shares automatically sold pursuant to irrevocable sell to cover elections entered into upon acceptance of the respective grants to satisfy tax withholding obligations in connection with the vesting of 2,550 RSUs from a January 6, 2021 grant of 10,200 RSUs and the vesting of 4,200 RSUs from a January 7, 2022 grant of 16,800 RSUs. Read SEC document |
| January 07, 2025 Filed Jan 10, 2025 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 1,599 | $45.34 | $72,498.66 |
DisclosureSEC source: 0001415889-25-001294 · form4-01102025_050109.xml · nonDerivative · entry 1 Pauwels Eric · CIK 0001323212 · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 88,941 F1 · shares: Represents shares automatically sold pursuant to an irrevocable sell to cover election entered into upon acceptance of the grant to satisfy tax withholding obligations in connection with the vesting of 4,500 RSUs from a January 5, 2023 grant of 18,000 RSUs. Read SEC document |
| January 03, 2025 Filed Jan 7, 2025 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | GrantStock Option (Right to Buy) · Derivative | 55,000 | $0.00 Strike: $46.54 | $0.00 |
DisclosureSEC source: 0001415889-25-001017 · form4-01072025_050105.xml · derivative · entry 2 Pauwels Eric · CIK 0001323212 · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 55,000 Underlying: Common Stock · 55,000 shares Expires 2035-01-02 F3 · derivative.exercise_date: This option was granted on January 3, 2025, and vests over four years, with 25% of the shares underlying the option vesting on January 3, 2026, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 3, 2026. Read SEC document |
| January 03, 2025 Filed Jan 7, 2025 22:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | GrantCommon Stock | 22,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-001017 · form4-01072025_050105.xml · nonDerivative · entry 1 Pauwels Eric · CIK 0001323212 · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 90,540 F1 · shares: Restricted stock units granted on January 3, 2025 that vest in four equal installments over four years, commencing on January 3, 2026. F2 · balance_after: Includes 445 shares of common stock acquired under the Issuer's employee stock purchase plan for the period ended June 30, 2024, and 401 shares of common stock acquired under the Issuer's employee stock purchase plan for the period ended December 31, 2024. Read SEC document |
| April 17, 2024 Filed Apr 19, 2024 21:20 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 787 | $25.14 | $19,781.25 |
DisclosureSEC source: 0001415889-24-011248 · form4-04192024_050404.xml · nonDerivative · entry 1 Pauwels Eric · CIK 0001323212 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 67,694 F1 · shares: Represents shares automatically sold pursuant to an irrevocable sell to cover election entered into upon acceptance of the grant to satisfy tax withholding obligations in connection with the vesting of 2,500 RSUs from an April 16, 2020 grant of 10,000 RSUs. Read SEC document |
| February 15, 2024 Filed Feb 16, 2024 22:00 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | GrantStock Option (Right to Buy) · Derivative | 55,000 | $0.00 Strike: $25.69 | $0.00 |
DisclosureSEC source: 0001415889-24-004162 · form4-02162024_050202.xml · derivative · entry 3 Pauwels Eric · CIK 0001323212 · CHIEF BUSINESS OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 55,000 Underlying: Common Stock · 55,000 shares Expires 2034-02-14 F3 · derivative.exercise_date: This option was granted on February 15, 2024, and vests over four years, with 25% of the shares underlying the option vesting on February 15, 2025, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on May 15, 2025. Read SEC document |
| February 15, 2024 Filed Feb 16, 2024 22:00 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | GrantCommon Stock | 2,300 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-004162 · form4-02162024_050202.xml · nonDerivative · entry 2 Pauwels Eric · CIK 0001323212 · CHIEF BUSINESS OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 68,481 F2 · shares: Restricted stock units granted on February 15, 2024 that vest in two equal installments over two years, commencing on February 15, 2025. Read SEC document |
| February 15, 2024 Filed Feb 16, 2024 22:00 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | GrantCommon Stock | 22,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-004162 · form4-02162024_050202.xml · nonDerivative · entry 1 Pauwels Eric · CIK 0001323212 · CHIEF BUSINESS OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 66,181 F1 · shares: Restricted stock units granted on February 15, 2024 that vest in four equal installments over four years, commencing on February 15, 2025. Read SEC document |
| January 30, 2024 Filed Feb 1, 2024 21:16 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 366 | $27.25 | $9,973.79 |
DisclosureSEC source: 0001415889-24-002171 · form4-02012024_090228.xml · nonDerivative · entry 1 Pauwels Eric · CIK 0001323212 · CHIEF BUSINESS OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 44,181 F1 · shares: Represents shares automatically sold pursuant to an irrevocable sell to cover election entered into upon acceptance of the grant to satisfy tax withholding obligations in connection with the vesting of 1,198 RSUs from a January 29, 2020 grant of 4,790 RSUs. Read SEC document |
| January 09, 2024 Filed Jan 10, 2024 21:09 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 2,065 | $29.01 | $59,915.56 |
DisclosureSEC source: 0001415889-24-000917 · form4-01102024_090157.xml · nonDerivative · entry 2 Pauwels Eric · CIK 0001323212 · CHIEF BUSINESS OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 44,547 F3 · shares: Represents shares automatically sold pursuant to irrevocable sell to cover elections entered into upon acceptance of the respective grants to satisfy tax withholding obligations in connection with the vesting of 2,550 RSUs from a January 6, 2021 grant of 10,200 RSUs and the vesting of 4,200 RSUs from a January 7, 2022 grant of 16,800 RSUs Read SEC document |
| January 08, 2024 Filed Jan 10, 2024 21:09 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 1,569 | $28.64 | $44,936.63 |
DisclosureSEC source: 0001415889-24-000917 · form4-01102024_090157.xml · nonDerivative · entry 1 Pauwels Eric · CIK 0001323212 · CHIEF BUSINESS OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 46,612 F1 · shares: Represents shares automatically sold pursuant to an irrevocable sell to cover election entered into upon acceptance of the grant to satisfy tax withholding obligations in connection with the vesting of 4,500 RSUs from a January 5, 2023 grant of 18,000 RSUs. F2 · balance_after: Includes 327 shares of common stock acquired under the Issuer's employee stock purchase plan for the period ending June 30, 2023 and 301 shares of common stock acquired under the Issuer's employee stock purchase plan for the period ending December 31, 2023. Read SEC document |
| May 22, 2023 Filed May 23, 2023 20:05 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 100 | $59.66 | $5,966.00 |
DisclosureSEC source: 0001415889-23-008568 · form4-05232023_080529.xml · nonDerivative · entry 3 Pauwels Eric · CIK 0001323212 · CHIEF BUSINESS OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 47,553 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on September 13, 2022. Read SEC document |
| May 22, 2023 Filed May 23, 2023 20:05 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 1,913 | $58.98 | $112,825.49 |
DisclosureSEC source: 0001415889-23-008568 · form4-05232023_080529.xml · nonDerivative · entry 2 Pauwels Eric · CIK 0001323212 · CHIEF BUSINESS OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 47,653 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on September 13, 2022. F3 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $58.61 to $59.52 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| May 19, 2023 Filed May 23, 2023 20:05 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 6,403 | $58.96 | $377,490.79 |
DisclosureSEC source: 0001415889-23-008568 · form4-05232023_080529.xml · nonDerivative · entry 1 Pauwels Eric · CIK 0001323212 · CHIEF BUSINESS OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 49,566 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on September 13, 2022. F2 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $58.50 to $59.42 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| May 18, 2023 Filed May 19, 2023 20:04 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 788 | $58.71 | $46,266.87 |
DisclosureSEC source: 0001415889-23-008390 · form4-05192023_080525.xml · nonDerivative · entry 3 Pauwels Eric · CIK 0001323212 · CHIEF BUSINESS OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 55,969 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on September 13, 2022. F3 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $58.50 to $59.16 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| May 17, 2023 Filed May 19, 2023 20:04 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 7,248 | $58.50 | $424,008.00 |
DisclosureSEC source: 0001415889-23-008390 · form4-05192023_080525.xml · nonDerivative · entry 2 Pauwels Eric · CIK 0001323212 · CHIEF BUSINESS OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 56,757 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on September 13, 2022. Read SEC document |
| May 17, 2023 Filed May 19, 2023 20:04 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 800 | $58.52 | $46,814.00 |
DisclosureSEC source: 0001415889-23-008390 · form4-05192023_080525.xml · nonDerivative · entry 1 Pauwels Eric · CIK 0001323212 · CHIEF BUSINESS OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 64,005 F1 · kind: This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on September 13, 2022. F2 · price: This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $58.50 to $58.53 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| April 18, 2023 Filed Apr 20, 2023 20:07 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 732 | $52.04 | $38,095.99 |
DisclosureSEC source: 0001415889-23-006752 · form4-04202023_080433.xml · nonDerivative · entry 1 Pauwels Eric · CIK 0001323212 · CHIEF BUSINESS OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 64,805 F1 · kind: Represents shares automatically sold pursuant to an irrevocable sell to cover election to satisfy tax withholding obligations in connection with the vesting of 2,500 RSUs from an April 16, 2020 grant of 10,000 RSUs. Read SEC document |
| January 31, 2023 Filed Feb 2, 2023 21:21 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 375 | $45.63 | $17,110.50 |
DisclosureSEC source: 0001415889-23-001800 · form4-02022023_090223.xml · nonDerivative · entry 1 Pauwels Eric · CIK 0001323212 · CHIEF BUSINESS OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,537 F1 · shares: Represents shares automatically sold pursuant to an irrevocable sell to cover election to satisfy tax withholding obligations in connection with the vesting of 1,197 RSUs from a January 29, 2020 grant of 4,790 RSUs. Read SEC document |
| January 24, 2023 Filed Jan 26, 2023 21:23 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 359 | $47.45 | $17,035.02 |
DisclosureSEC source: 0001415889-23-001460 · form4-01262023_090158.xml · nonDerivative · entry 1 Pauwels Eric · CIK 0001323212 · CHIEF BUSINESS OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,912 F1 · shares: Represents shares automatically sold pursuant to an irrevocable sell to cover election to satisfy tax withholding obligations in connection with the vesting of 1,155 shares of restricted stock from a January 22, 2019 grant of 4,620 shares of restricted stock. Read SEC document |
| January 11, 2023 Filed Jan 12, 2023 21:35 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 571 | $44.36 | $25,329.33 |
DisclosureSEC source: 0001415889-23-000878 · form4-01122023_090113.xml · nonDerivative · entry 2 Pauwels Eric · CIK 0001323212 · CHIEF BUSINESS OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,271 F1 · shares: Represents shares automatically sold pursuant to an irrevocable sell to cover election to satisfy tax withholding obligations in connection with the vesting of 4,200 RSUs from a January 7, 2022 grant of 16,800 RSUs. Read SEC document |
| January 10, 2023 Filed Jan 12, 2023 21:35 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 663 | $42.93 | $28,464.51 |
DisclosureSEC source: 0001415889-23-000878 · form4-01122023_090113.xml · nonDerivative · entry 1 Pauwels Eric · CIK 0001323212 · CHIEF BUSINESS OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,842 F1 · shares: Represents shares automatically sold pursuant to an irrevocable sell to cover election to satisfy tax withholding obligations in connection with the vesting of 4,200 RSUs from a January 7, 2022 grant of 16,800 RSUs. Read SEC document |
| January 09, 2023 Filed Jan 11, 2023 23:12 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | SaleCommon Stock | 858 | $41.66 | $35,741.02 |
DisclosureSEC source: 0001415889-23-000835 · form4-01112023_110128.xml · nonDerivative · entry 1 Pauwels Eric · CIK 0001323212 · CHIEF BUSINESS OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,505 F1 · shares: Represents shares automatically sold pursuant to an irrevocable sell to cover election to satisfy tax withholding obligations in connection with the vesting of 2,550 RSUs from a January 6, 2021 grant of 10,200 RSUs. Read SEC document |
| January 05, 2023 Filed Jan 9, 2023 21:54 UTC | PTC THERAPEUTICS, INC. PTCT · Entity 3803 | GrantStock Option (Right to Buy) · Derivative | 45,000 | $0.00 Strike: $39.42 | $0.00 |
DisclosureSEC source: 0001415889-23-000690 · form4-01092023_090159.xml · derivative · entry 2 Pauwels Eric · CIK 0001323212 · CHIEF BUSINESS OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 45,000 shares Expires 2033-01-04 F3 · derivative.exercise_date: This option was granted on January 5, 2023, and vests over four years, with 25% of the shares underlying the option vesting on January 5, 2024, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 5, 2024. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.